Loading...
•
Dec 31, 2022
Co-Diagnostics Q4 2022 Earnings Report
Full year results were impacted by lower demand for COVID-19 testing, and clinical evaluations for Co-Dx PCR Home™ Platform were initiated.
Key Takeaways
Co-Diagnostics reported full year 2022 financial results, impacted by decreased demand for COVID-19 testing. The company is focusing on its Co-Dx PCR Home™ platform and its potential beyond COVID-19.
COVID-19's impact on society decreased, leading to lower demand for high-throughput testing.
Progress was made against strategic priorities supporting the Co-Dx PCR Home™ platform.
Clinical evaluations for the Co-Dx PCR Home platform commenced in February.
The company remains focused on clinical evaluations for its Co-Dx PCR Home platform and regulatory submissions.
Co-Diagnostics
Co-Diagnostics
Forward Guidance
The company remains focused on executing the clinical evaluations for our Co-Dx PCR Home platform, including the clinical trials themselves and the analytical studies required to support regulatory submissions.